A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer

Summary

Based on indicators such as 24 week progression free survival (24 weeks PFS) in small cell lung cancer (SCLC) patients without disease progression after first-line platinum containing chemotherapy, objective response rate (ORR) in SCLC patients with recurrence or progression after first-line platinum containing chemotherapy, and orr in SCLC patients with recurrence or progression after second-line and above treatment,Evaluation of the effectiveness of al8326 monotherapy in small cell lung cancer.

Timeline

Start

2020-10-19

Primary completion

2021-09

Completion

2021-09

Drugs

Indications